Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707717 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
A Phase 1 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 1
- Development phase
- 189
- Enrollment target
NCT03707717 is a Phase 1 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 189 participants.
The verdict
NCT03707717, a Phase 1 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 189 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03707717
The ClinicalTrials.gov registry entry for NCT03707717 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03707717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03707717 about?
NCT03707717 is a clinical study titled "A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants". The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
What is the current status of trial NCT03707717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 189 participants. The study started on 2018-10-15. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT03707717?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03707717?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.